KEGG   DRUG: Clopidogrel sulfate and aspirin
Entry
D10513            Mixture   Drug                                   

Name
Clopidogrel sulfate and aspirin;
Clopidogrel and acetylsalicyclic acid;
Complavin (TN)
Component
(Clopidogrel sulfate [DR:D00769] | Clopidogrel [DR:D07729]), Aspirin [DR:D00109]
Remark
Therapeutic category: 3399
Product: D10513<JP>
Efficacy
Antiplatelet
Comment
Clopidogrel is metabolized to an active metabolite mainly by CYP2C19, and CYP1A2, CYP2B6 and CYP3A4 contribute to the generation of the active metabolite, and Clopidogrel glucuronate conjugate is an inhibitor of CYP2C8.
Metabolism
Enzyme: CYP2C19 [HSA:1557]; CYP1A2 [HSA:1544], CYP2B6 [HSA:1555], CYP3A4 [HSA:1576]
Interaction
CYP inhibition: CYP2C8 [HSA:1558]
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  33  Blood and body fluid agents
   339  Miscellaneous
    3399  Others
     D10513  Clopidogrel sulfate and aspirin
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10513
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10513
Other DBs
PubChem: 172232606

» Japanese version   » Back

DBGET integrated database retrieval system